Table 1.
Baseline patient characteristics
| EGFR-TKI (N = 101) | Chemotherapy N = 54 | P | |
|---|---|---|---|
| Age, y | 0.38 | ||
| Median (range) | 63 (35–84) | 60 (32–85) | |
| Gender, n (%) | 0.04 | ||
| Male | 23 (23) | 21 (39) | |
| Female | 78 (77) | 33 (61) | |
| Race, n (%) | <0.01 | ||
| White, non-Hispanic | 86 (85) | 50 (92) | |
| Asian | 12 (12) | 0 (0) | |
| Black | 3 (3) | 2 (4) | |
| Hispanic | 0 (0) | 2 (4) | |
| Smoking history, n (%) | 0.05 | ||
| Never-smoker | 58 (57) | 20 (37) | |
| ≤10 pack-years | 19 (19) | 16 (30) | |
| >10 pack-years | 24 (24) | 18 (33) | |
| ECOG PS, n (%)a | 0.34 | ||
| 0–1 | 95 (94) | 46 (85) | |
| ≥2 | 6 (6) | 6 (11) | |
| Histology, n (%) | 0.11 | ||
| Adenocarcinoma | 92 (91) | 47 (87) | |
| Squamous | 0 (0) | 2 (4) | |
| Large cell carcinoma | 0 (0) | 1 (2) | |
| NSCLC NOS | 9 (9) | 4 (7) | |
| Stageb, n (%) | 0.43 | ||
| Relapsedc | 19 (19) | 6 (11) | |
| IVA | 34 (34) | 18 (33) | |
| IVB | 48 (48) | 30 (56) | |
| Prior BM, n (%) | 24 (24) | 12 (22) | 1.00 |
| Prior therapy for BM no. | — | ||
| Radiation | 21 | 6 | |
| Resection and radiation | 1 | 4 | |
| None | 2 | 2 | |
| First-line chemotherapy, n (%) | — | ||
| Platinum doublet | — | 49 (91) | |
| Single agent | — | 4 (7) | |
| Other combination | — | 1 (2) | |
| First-line EGFR-TKI, n (%) | — | ||
| Gefitinib | 11 (11) | — | |
| Erlotinib | 90 (89) | — |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; NOS, not otherwise specified.
a
Data not available for 2 patients in the chemotherapy group.
b
American Joint Committee on Cancer staging system 7th edition.
c
Patients with stage I-IIIA NSCLC with systemic relapse following definitive therapy that included surgical resection.